21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
22:41 , May 2, 2019 |  BC Extra  |  Company News

Management tracks: Akero, NIH, Arcus

Metabolic disease company Akero Therapeutics Inc. (South San Francisco, Calif.) hired Bill White as its first CFO and head of corporate development. He was a managing director and head of U.S. life sciences investment banking...
04:00 , Jan 4, 2019 |  BC Week In Review  |  Financial News

New $250M Atlas fund to target later-stage investments

Atlas Venture closed on Jan. 2 its oversubscribed Atlas Venture Opportunity Fund I at $250 million, intended to support growth for Akero Therapeutics Inc. (South San Francisco, Calif.) and other existing portfolio companies. Atlas told...
18:19 , Jan 2, 2019 |  BC Extra  |  Financial News

New $250M Atlas fund to target later-stage investments

Atlas Venture closed its oversubscribed Atlas Venture Opportunity Fund I at $250 million, intended to support growth for Akero Therapeutics Inc. (South San Francisco, Calif.) and other existing portfolio companies. Atlas told BioCentury the fund...
19:11 , Dec 14, 2018 |  BC Week In Review  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
18:27 , Dec 12, 2018 |  BC Extra  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
19:57 , Oct 18, 2018 |  BC Extra  |  Company News

Management tracks: Autolus, Bayer, Cambridge Allergy

T cell cancer therapy company Autolus Therapeutics plc (NASDAQ:AUTL) hired Adam Hacker as SVP for regulatory affairs and quality, a newly created position. Previously, he was VP, head of vaccines and scientific innovation projects, global...
23:10 , Oct 17, 2018 |  BC Extra  |  Company News

Management tracks: Ziopharm, Merck

Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) said CMO and EVP of R&D Francois Lebel will step down, effective Oct. 26. Merck & Co. Inc. (NYSE:MRK) hired Jim Scholefield as chief information and digital officer. He...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...